

Massimiliano Cadamuro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2825698/publications.pdf>

Version: 2024-02-01

79
papers

2,578
citations

172207

29
h-index

197535

49
g-index

82
all docs

82
docs citations

82
times ranked

3405
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. <i>Hepatology</i> , 2013, 58, 1042-1053.	3.6	139
2	Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. <i>Hepatology</i> , 2006, 43, 1001-1012.	3.6	138
3	Analysis of Liver Repair Mechanisms in Alagille Syndrome and Biliary Atresia Reveals a Role for Notch Signaling. <i>American Journal of Pathology</i> , 2007, 171, 641-653.	1.9	120
4	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, 700-709.	1.8	112
5	Ursodeoxycholic Acid Stimulates Cholangiocyte Fluid Secretion in Mice via CFTR-Dependent ATP Secretion. <i>Gastroenterology</i> , 2007, 133, 1603-1613.	0.6	104
6	Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. <i>PLoS ONE</i> , 2017, 12, e0169854.	1.1	103
7	ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice. <i>Gastroenterology</i> , 2010, 138, 360-371.e7.	0.6	90
8	Diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 108-122.	1.9	89
9	Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. <i>Hepatology</i> , 2010, 51, 1778-1788.	3.6	87
10	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. <i>Hepatology</i> , 2011, 54, 890-899.	3.6	82
11	Macrophage recruitment by fibrocystin β -defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. <i>Hepatology</i> , 2016, 63, 965-982.	3.6	80
12	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 497-511.	8.2	73
13	Cholangiocarcinoma. <i>Pathologica</i> , 2021, 113, 158-169.	1.3	70
14	Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. <i>World Journal of Hepatology</i> , 2017, 9, 455.	0.8	69
15	Emerging concepts in biliary repair and fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G102-G116.	1.6	63
16	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
17	Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. <i>Hepatology</i> , 2008, 47, 719-728.	3.6	60
18	The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1435-1443.	1.8	56

#	ARTICLE	IF	CITATIONS
19	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e21369.	1.1	56
20	The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology, 2016, 64, 2118-2134.	3.6	55
21	Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Oncotarget, 2015, 6, 26052-26064.	0.8	51
22	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research, 2016, 76, 4775-4784.	0.4	44
23	Protein kinase a-dependent pSer ⁶⁷⁵ - β -catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology, 2013, 58, 1713-1723.	3.6	43
24	Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1374-1379.	1.8	41
25	Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?. Journal of Clinical Medicine, 2015, 4, 2028-2041.	1.0	39
26	Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 954-964.	1.8	39
27	β -catenin and interleukin-1 β -dependent chemokine (CXCL10) production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology, 2018, 67, 1903-1919.	3.6	38
28	Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: A novel in vitro model to study tumor-stroma interactions. Oncology Reports, 2013, 30, 1143-1148.	1.2	33
29	Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype. Stem Cells International, 2016, 2016, 1-10.	1.2	33
30	Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica, 2021, 113, 170-184.	1.3	32
31	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut, 2011, 60, 108-115.	6.1	30
32	Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. International Journal of Molecular Sciences, 2017, 18, 149.	1.8	30
33	New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Reports, 2021, 3, 100251.	2.6	28
34	Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Translational Gastrointestinal Cancer, 2013, 2, 130-144.	3.0	27
35	Nephrosphere-Derived Cells Are Induced to Multilineage Differentiation when Cultured on Human Decellularized Kidney Scaffolds. American Journal of Pathology, 2018, 188, 184-195.	1.9	25
36	Isolated idiopathic bile ductular hyperplasia in patients with persistently abnormal liver function tests. Journal of Hepatology, 2004, 40, 592-598.	1.8	24

#	ARTICLE	IF	CITATIONS
37	Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/ β 2 Catenin Signalling Activation. <i>Genes</i> , 2018, 9, 522.	1.0	24
38	Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3875.	1.8	21
39	Animal models of cholangiocarcinoma: What they teach us about the human disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 403-415.	0.7	21
40	Fibrocystic liver disease: novel concepts and translational perspectives. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 26-26.	1.5	21
41	Molecular Pathology Analysis of SARS-CoV-2 in Syncytiotrophoblast and Hofbauer Cells in Placenta from a Pregnant Woman and Fetus with COVID-19. <i>Pathogens</i> , 2021, 10, 479.	1.2	20
42	Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. <i>Advances in Cancer Research</i> , 2021, 149, 321-387.	1.9	18
43	Notch signaling and progenitor/ductular reaction in steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0187384.	1.1	18
44	Liver Matrix in Benign and Malignant Biliary Tract Disease. <i>Seminars in Liver Disease</i> , 2020, 40, 282-297.	1.8	17
45	Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. <i>Gene Expression</i> , 2018, 18, 31-50.	0.5	16
46	The patient presenting with isolated hyperbilirubinemia. <i>Digestive and Liver Disease</i> , 2009, 41, 375-381.	0.4	14
47	Necroptosis in Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 982.	1.8	13
48	APOA-1Milano mutants, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in ApoE atherosclerotic mice. <i>International Journal of Cardiology</i> , 2018, 271, 233-239.	0.8	11
49	The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 115.	1.2	11
50	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	1.8	11
51	Animal models for cystic fibrosis liver disease (CFLD). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 965-969.	1.8	9
52	Obeticholic acid reduces biliary and hepatic matrix metalloproteinases activity in rat hepatic ischemia/reperfusion injury. <i>PLoS ONE</i> , 2020, 15, e0238543.	1.1	9
53	The Neglected Role of Bile Duct Epithelial Cells in NASH. <i>Seminars in Liver Disease</i> , 2022, 42, 034-047.	1.8	8
54	Evidence of vertical transmission of SARS-CoV-2 and interstitial pneumonia in second-trimester twin stillbirth in asymptomatic woman. Case report and review of the literature. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022, 4, 100589.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Benign biliary neoplasms and biliary tumor precursors. <i>Pathologica</i> , 2021, 113, 147-157.	1.3	7
56	Anti-Inflammatory and Pro-Regenerative Effects of Hyaluronan-Chitlac Mixture in Human Dermal Fibroblasts: A Skin Ageing Perspective. <i>Polymers</i> , 2022, 14, 1817.	2.0	7
57	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	1.9	5
58	Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 1086.	1.1	5
59	Cholangiocyte Biology as Relevant to Cystic Liver Diseases. , 2010, , 23-43.		3
60	JNK signaling activated by Platelet-Derived Growth Factor D (PDGF-D) stimulates secretion of Vascular Endothelial Growth Factor-C (VEGF-C) by cancer-associated fibroblasts to promote lymphangiogenesis and early metastatization in cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, e22-e23.	0.4	2
61	Mo1472 Secretion of Vascular Endothelial Growth Factor-C by Cancer-Associated Fibroblasts (CAF) Is Stimulated by Platelet-Derived Growth Factor D (PDGF-D) and Promotes Lymphangiogenesis in Cholangiocarcinoma. <i>Gastroenterology</i> , 2016, 150, S1124.	0.6	2
62	Olfactory neuroepithelium alterations and cognitive correlates in schizophrenia. <i>European Psychiatry</i> , 2019, 61, 23-32.	0.1	2
63	Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 232-235.	0.7	2
64	Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche. <i>Journal of Hepatology</i> , 2021, 74, 771-774.	1.8	2
65	Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. <i>Advances in Cancer Research</i> , 2022, , .	1.9	2
66	Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1 mouse model of congenital hepatic fibrosis. <i>FASEB Journal</i> , 2022, 36, e22364.	0.2	2
67	The Healthy Biliary Tree: Cellular and Immune Biology. , 2017, , 17-41.		1
68	A Ploidy Increase Promotes Sensitivity of Glioma Stem Cells to Aurora Kinases Inhibition. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	0.6	1
69	Fibrocystic liver disease: novel concepts and translational perspectives. <i>Translational Gastroenterology and Hepatology</i> , 0, 6, 26-26.	1.5	1
70	Evidence for epithelialâ€mesenchymal transition in the biliary epithelium of human cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2008, 40, A10-A11.	0.4	0
71	Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor. , 2019, , 167-182.		0
72	THU-493-Reciprocal changes in ARID1A and EZH2 are associated with cholangiocarcinoma development in a mouse model of caroli disease with high Yap expression. <i>Journal of Hepatology</i> , 2019, 70, e377-e378.	1.8	0

#	ARTICLE	IF	CITATIONS
73	SAT-389-Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury. <i>Journal of Hepatology</i> , 2019, 70, e805.	1.8	0
74	FRI-011-Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e387-e388.	1.8	0
75	Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2019, 51, e1.	0.4	0
76	Congenital Cystic Lesions of the Biliary Tree. , 2021, , 19-46.		0
77	Unmet needs in basic and translational research in Cholangiocarcinoma. <i>Liver Cancer International</i> , 0, , .	0.2	0
78	Personalized molecular targeted therapy for hepatocellular carcinoma in the era of genome sequencing. <i>Translational Cancer Research</i> , 2016, 5, S420-S424.	0.4	0
79	How to mimic a histological sample slide for RNAscope TM applications from BAL cytological specimens. <i>Journal of Cytology</i> , 2021, 38, 231.	0.2	0